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Cancer is a devastating disease for human society with thousands of deaths and 
estimated new cases every year around the globe. Intensive research efforts on 
understanding the disease progression and determining effective diagnostics and 
therapeutics have been employed for over one hundred years. Throughout this time, and 
in particular during the last two decades, computational-based methods have gained 
increasing importance in cancer biology research by providing significant advantages in 
the analysis and interpretation of high-throughput data at the molecular and genomic 
levels.  
More specifically, after completion of the Human Genome Project in 2003, and 
with the Cancer Human Genome Project underway, high-throughput biological assays 
(e.g., microarray chips, next generation sequencing machines) have supplied researchers 
thousands of measurements per experimental sample. The massive amount of related data 
has oftentimes been challenging to interpret and translate, particularly in cancer biology 
and therapeutics. This thesis reports the results of  three independent studies in which 
high-throughput gene expression is computationally analyzed to address longstanding 
issues in cancer biology. Two of the studies utilize data from ovarian cancer patients 
while the third involves data collected from pancreatic cancer patients.   
In Chapter 1, I address the importance of personalized profiling in pancreatic cancer ; in 
Chapter 2  the role of cancer stroma in the progression of ovarian cancer and in Chapter 3 
evidence for the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer 
metastasis. 
More specifically, Chapter 1 emphasizes the power of personalized molecular 
profiling in unmasking unique gene expression signatures that correspond to each 
individual patient. These individual expression patterns (individual profiling), which may 
be overlooked by the traditional methods of gene signatures enriched in groups of 
afflicted individuals (group profiling), can provide valuable information for more 
successful targeted therapies. In order to address this issue in pancreatic cancer, 
comparisons of the most significantly differentially expressed genes and functional 
 xii 
pathways were performed between cancer and control patient samples as determined by 
group vs. personalized analyses. There was little to no overlap between genes/pathways 
identified by group analyses relative to those identified by personalized analyses. These 
results indicated that personalized and not group molecular profiling is the most 
appropriate approach for the identification of putative candidates for targeted gene 
therapy of pancreatic and perhaps other cancers with heterogeneous molecular etiology.        
Chapter 2, also with strong implications on personalized molecular profiling, 
unveils the functional variability of the tumor microenvironment among ovarian cancer 
patients. The purpose of this study was to investigate the process of microenvironmental 
stroma activation in human ovarian cancer by molecular analysis of matched sets of 
cancer and surrounding stroma tissues from individual patients. Expression patterns of 
genes encoding signaling molecules and compatible receptors in the cancer stroma and 
cancer epithelia samples indicated the existence of two sub-groups of cancer stroma with 
different propensities to support tumor growth. These results demonstrated that 
functionally significant variability exists among ovarian cancer patients in the ability of 
the microenvironment to modulate cancer development.  
Chapter 3 aims to uncover the molecular mechanisms that underlie the metastatic 
process with the hope that such knowledge may lead to more effective therapeutic 
treatments. For this purpose, pathological and molecular analyses were conducted in 14 
matched sets of primary and metastatic samples from late staged ovarian cancer patients. 
Pathological examination revealed no morphological differences between any of the 
primary and metastatic samples.  In contrast, gene expression analyses identified two 
distinct groups of patient samples. One group displayed essentially identical expression 
patterns to primary samples isolated from the same patients. The second group displayed 
expression patterns significantly different from primary samples isolated from the same 
patients. Predominant among the differentially expressed genes characterizing this second 
class of metastatic samples were genes previously associated with epithelial-to-
mesenchymal transtion (EMT). These results supported a role of EMT in at least some 
ovarian cancer metastases and demonstrated that indistinguishable morphologies between 
primary and metastatic cancer samples is not sufficient evidence to negate the role of 




EVIDENCE FOR THE IMPORTANCE OF PERSONALIZED 
MOLECULAR PROFILING IN PANCREATIC CANCER 
1.1 Introduction 
 High-throughput molecular profiles (DNA and RNA sequencing, microarray gene 
expression analyses, etc.) are revolutionizing the way cancers are diagnosed [1-4], 
classified [5, 6] and treated [7-9]. One well-established approach to identify molecular 
variants (e.g., genetic, epigenetic, or gene expression pattern variants) that may be 
causally related to complex diseases such as cancer, is to identify variant patterns that are 
significantly enriched in groups of afflicted individuals relative to normal healthy 
controls. Examples of this approach are the various genome-wide association studies 
(GWAS) designed to identify disease-causing alleles [10, 11]. While the group approach 
can, by design, detect genetic or gene expression patterns that are in common among 
groups of afflicted individuals, genetic variants/molecular patterns that are unique to 
specific individuals, albeit of potential clinical significance, may go undetected using the 
group approach. This is likely to be especially true if there are multiple possible 
molecular paths to the same disease state as is believed to be the case for many, if not all, 
cancers [12].  
In this study, we were interested in evaluating the impact of employing a group 
vs. a personalized approach in the analysis of gene expression profiles of a series of 
pancreatic cancer patients. We found that the most significant genes/molecular pathways 
identified among these patients, when analyzed as a group, were substantially different 
from the significant genes/molecular pathways identified when the analysis was 
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performed on an individual patient basis. Our results are consistent with earlier DNA 
sequence studies [13, 14] indicating that, on the molecular level, pancreatic cancer is a 
highly heterogeneous disease and, as a consequence, personalized gene expression 
profiling is critical to the acquisition of clinically significant information  
 
1.2 Materials and Methods 
1.2.1 Tissue collection and cell extraction 
Patient tissues were collected at Northside Hospital (Atlanta, GA) under 
appropriate Institutional Review Board protocols. Following resection, the tumor tissues 
were examined by a pathologist and then placed in cryotubes and frozen in liquid 
nitrogen. Samples were transported on dry ice to Georgia Institute of Technology 
(Atlanta, GA), and stored at -80 ºC.  
The tissue samples were examined microscopically and histology of ductal 
adenocarcinoma was verified by a pathologist. Following the examination and 
verification, tissue samples were embedded in cryomatrix (Shandon, Fisher Scientific, 
Pittsburg, PA, USA), and 7μm frozen sections were cut and attached to uncharged 
microscope slides.  Immediately after dehydration and staining (HistoGene, LCM Frozen 
Section Staining Kit, Life Technologies, Carlsbad, CA, USA), slides were processed in 
an Autopix (Life Technologies) instrument for laser capture microdissection (LCM). For 
each of the four patients, three samples from their ductal epithelial tumor cells and three 
samples of their normal ductal epithelial cells were collected. All cells were isolated by 
LCM to ensure purity of samples. Approximately 30,000 cells were collected for each of 
the 24 total samples (12 cancer and 12 normal samples). 
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Table 1.1. Patient clinical information at the time of surgery and clinical outcome at the time of this study. 
 
PATIENT SEX/AGE TUMOR STAGE CLINICAL OUTCOME  
(months after surgery) 
P1 Male/77 T3N0MX II No Evidence of Disease (15) 
P2 Male/69 T3NXMX II Alive with Disease (16) 
P3 Female/55 T3N1M0 II No Evidence of Disease (8) 
P4 Female/67 T3N1MX II Distant Metastases (9) 
 
1.2.2 RNA extraction and amplification 
PicoPure RNA Isolation Kit (Life Technologies) protocols were followed for 
RNA extraction from the LCM cells on the Macro LCM caps in 30µL of extraction 
buffer. RNA quality was verified for all samples on the Bioanalyzer RNA Pico Chip 
(Agilent Technologies, Santa Clara, CA, USA). Total RNA from the above extractions 
was processed using Ovation® Pico WTA System (NuGEN) in conjunction with the 
Encore™ BiotinIL Module (NuGEN Technologies, San Carlos, CA, USA), to produce an 
amplified, biotin-labeled cDNA suitable for hybridizing to GeneChip Human Genome 
U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA) following manufacturer's 
recommendations. 
 
1.2.3 Microarray data analysis 
We generated 24 individual gene expression profiles from the three cancer and 
three normal biological replicate samples of the four patients. Affymetrix .CEL files were 
processed using the Affymetrix Expression Console (EC) Software Version 1.1 with the 
Robust Multi-Array Average (RMA) normalization method. The normalized expression 
values from all 24 samples were log2 transformed.  
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Group analysis: The initial data contained 54,675 probe set expression values of 
the Affymetrix Human Genome U133 Plus 2.0 chip. For the group analysis, the log2 
transformed values were averaged across the 12 cancer and 12 normal samples. An 
unpaired t-test (p-value ≤ 0.005) was applied to identify those probe sets (350) that had 
significantly different expressions among all 12 cancer and all 12 normal samples. These 
350 probe sets were employed in the group clustering analysis.  Out of these 350 probe 
sets, the 287 unique, annotated genes were ranked by fold change (FC). The FC of each 
gene was calculated by subtracting the average normal value from the average cancer 
value. Pathway analyses were carried out using the web-based integrated software suite 
MetaCore of GeneGO (http://thomsonreuters.com/products_services/science/systems-
biology/). Applying the default cutoff p-value ≤ 0.05, the 287 genes were found to be 
enriched for 22 pathways.  
Individual patient analysis: For the individual patient analysis, the log2 
transformed values were averaged across each individual’s cancer and normal replicate 
samples. From each of the patient’s initial 54,675 probe sets, an unpaired t-test (p-value ≤ 
0.005) was applied to identify 188, 267, 435 and 291 probe sets that had significantly 
different expression between the cancer and normal replicate samples for each of the 
patients P1, P2, P3 and P4, respectively. As in the group analysis, these probe sets were 
employed in the individual clustering analyses (heat maps). Out of these, the 148, 221, 
362 and 220 unique, annotated genes for P1, P2, P3 and P4, respectively, were ranked 
according to FC. The FC of each gene was calculated by subtracting the average normal 
value from the average cancer value for each individual. These genes also were used in 
the pathway analyses as described above (MetaCore GeneGO software suite). Applying 
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the default cutoff p-value ≤ 0.05, the genes were found to be significantly enriched for 
15, 17, 25 and 30 pathways in P1, P2, P3 and P4, respectively.  For the probe set 
clusterings (heat maps) in both the group and individual analyses, the log2 transformed 
values were normalized by Z-score statistics. 
 
Analysis of data from the previously published study of Badea et al [15]: Seventy-
eight Affymetrix .CEL files were downloaded from the GEO Omnibus database with 
accession number GDS4103. The files were processed using the Affymetrix Expression 
Console (EC) Software Version 1.1 with the Robust Multi-Array Average (RMA) 
normalization method, and the normalized expression values were log2 transformed, 
similarly to our sample analysis. All the 78 samples from 36 patients were used for the 
group analysis. For the individual analysis, the available two replicate cancer and two 
replicate normal samples from three patients were used (here-in referred to as patients P5, 
P6 and P7; 12 samples total). Both the group and the individual analyses were performed 
using the methods described above. Because technical replicates (multiple assays of the 
same biological patient sample) rather than biological replicates (assays of multiple 
biological samples from the same patient), as assayed in our study, were used in the 
Baeda et al study, the number of significantly differentiated genes at p ≤ 0.005 was more 
than an order of magnitude greater than in our study. Thus, we employed an unpaired t-
test with a more stringent cut off (p ≤ 0.00001) than in our analysis in order to keep the 
number of significantly differentiated genes comparable to our study. Using this criterion, 
17,658 significantly differentially expressed probe sets were detected, of which the 500 
(330 annotated, unique genes) most significant were used for further analysis. For the 
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individual gene analysis, the same unpaired t-test with p-value ≤ 0.00001 identified 12, 
37 and 22 significant probe sets (12, 29 and 20 annotated, unique genes) in patients P5, 
P6 and P7, respectively.  
 
1.3 Results 
1.3.1 Group profiling identifies genes and functional pathways previously implicated in 
pancreatic and other cancers 
Genes: In the group profiling, all 12 cancer samples were compared against all 12 
normal samples, and 350 probe sets (287 genes) were found to display significant 
differences in expression (p-value ≤ 0.005). The clustering of these 350 probe sets 
presented in Figure 1.1 demonstrates clear separation of the cancer and control samples. 
However, multiple samples taken from the same patient do not consistently cluster 
together indicating heterogeneity within both the cancer and control groups.  
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Figure 1.1. Hierarchical clustering of the 350 probe sets that display a significant (p-value ≤ 0.005) 
difference in gene expression among all Cancer and Normal samples. The heatmap was generated by z-
score normalization of log2 expression values from the Affymetrix HG U133 Plus 2.0 chip. Patients are 
denoted as P1, P2, P3, and P4 with their associated cancer and normal biological replicate samples (i.e., C1, 
C2, C3, and N1, N2, N3, respectively). 
 
Table 1.2 presents the top 20 most significant differentially expressed genes (ten 
most significantly up-regulated and ten most significantly down-regulated) between the 
normal and cancer samples as ranked by FC (a complete listing of significantly 
differentiated genes is presented in Tables A.1.1 and A.1.2).  
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Table 1.2. The ten most significantly up-regulated and the ten most significantly down-regulated genes in 
cancer resulting from the group analysis of the 287 unique, annotated, significantly differentially expressed 
genes. 
Probe Set ID Gene Symbol Fold 
Change 
p-value 
204351_at S100P 2.514003 0.001932 
242271_at SLC26A9 2.178434 0.000706 
219014_at PLAC8 1.960672 0.000116 
239196_at ANKRD22 1.953161 0.004337 
239609_s_at LPCAT4 1.849687 0.00536 
205769_at SLC27A2 1.824208 0.001088 
238021_s_at CRNDE 1.768419 0.000247 
58916_at KCTD14 1.749122 0.000353 
213611_at AQP5 1.690754 0.000406 
217109_at MUC4 1.636676 0.000648 
209277_at TFPI2 -2.73483 0.001026 
223761_at FGF19 -2.67697 0.000627 
204437_s_at FOLR1 -2.52475 0.000341 
1554690_a_at TACC1 -2.15521 0.000136 
214844_s_at DOK5 -2.12474 0.004549 
216598_s_at CCL2 -2.1185 0.000506 
223449_at SEMA6A -2.10883 0.001156 
207392_x_at UGT2B15 -1.99045 0.000764 
204151_x_at AKR1C1 -1.95521 0.00026 
222901_s_at KCNJ16 -1.93938 0.002889 
 
Among the up-regulated genes in cancer was S100P (S100 calcium binding 
protein P), a member of the S100 protein family that has been associated with regulation 
of cell cycle progression and previously implicated in the etiology of prostate and 
pancreatic cancer [16, 17]. Also up-regulated was ANKRD22 (ankyrin repeat domain 22), 
a gene previously found to be significantly up-regulated in the peripheral blood cells of 
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pancreatic cancer patients [18]. Other genes that were up-regulated in the cancer samples 
as determined in the group analysis are MUC4 (mucin-4 cell surface associated), CRNDE 
(colorectal neoplasia differentially expressed), and AQP5 (aquaporin 5). MUC4 encodes 
a high-molecular weight glycoprotein that previously has been reported to be up 
regulated in pancreatic [19] and other cancers [20], and is believed to facilitate tumor 
growth and metastasis. CRNDE is a long non-coding RNA gene elevated in colorectal 
cancer [21].(AQP5) is a putative oncogene [22] that has been associated with increased 
proliferation and metastatic potential in breast cancer [23], lung cancer [24], non-small 
cell lung cancer [25], colorectal cancer [26], and chronic myelogenous leukemia [27].    
Among the genes significantly down regulated in the cancer samples, TFPI-2 (tissue 
factor pathway inhibitor 2) encodes a Kunitz-type serine proteinase inhibitor believed to 
regulate extracellular matrix digestion and remodeling [28]. Hyper-methylation of the 
TFPI-2 promoter and consequent down-regulation in expression has been previously 
associated with the onset of pancreatic ductal adenocarcinomas [29] and other 
carcinomas [30]. Methylation of TFPI-2 has also been recently proposed as a potential 
biomarker for the early detection of colorectal cancer [31]. Also significantly down 
regulated was FGF19 (fibroblast growth factor 19), a member of the fibroblast growth 
factor (FGF) gene family that has been implicated in a variety of cancers [32]. Other 
genes found to be significantly down regulated in cancer tissues by the group analysis 
were CCL2 (chemokine (C-C motif) ligand 2) and TACC1 (transforming, acidic coiled-
coil containing protein 1). CCL2 is a chemokine that attracts mononuclear cells and 
possesses a dual role in cancer. In some instances, CCL2 is involved in anti-tumor host 
activities, but in others it is secreted by cancer cells and it enhances cancer growth [33]. 
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Loss of human TACC genes, TACC1 and TACC3, underlies a significant portion of 
ovarian cancers [34].  
 Pathways: Functional analysis was carried out with the integrated software 
suite MetaCore of GeneGO 
(http://thomsonreuters.com/products_services/science/systems-biology/) incorporating 
the 287 differentially expressed genes. The analysis identified 22 significantly enriched 
functional pathways (p ≤ 0.05, Table 1.3). More than half of the 22 pathways were 
associated with the immune response (12/22). Oncostatin M appeared in 4 out of the 12 
immune response pathways. Oncostatin M is a member of a cytokine family that includes 
leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6, and 
it possesses the ability to inhibit the proliferation of cells in lines derived from several 
tumor types, including breast carcinoma, ovarian cancer, melanoma, glioma and lung 
carcinoma [35]. The two most significantly enriched pathways involve  androstenedione 
and testosterone biosynthesis and metabolism (i.e., androgen metabolism), both of which 
have been found significantly altered in pancreatic cancer [36]. Other immune response 
pathways from the group functional analysis were related to interleukins IL-13, IL-17 and 
IL-18. IL-13 was previously shown to play a pivotal role in the immunoregulatory 
pathway of NKT cells that suppress tumor immunosurveillance [37]. Although IL-17 
seems to have been previously associated with both tumor regression and tumor growth 
[38], the specific IL-17 immune response pathway enriched in our analysis contained the 




Table 1.3. The 22 significantly enriched pathways (p ≤ 0.05) of the differentially expressed genes from the 
group analysis (287 genes). 
GROUP ANALYSIS PATHWAYS p-Value 
Androstenedione and testosterone biosynthesis and metabolism p.2 0.000342 
Androstenedione and testosterone biosynthesis and metabolism p.2/ Rodent version 0.000362 
Immune response_Oncostatin M signaling via JAK-Stat in mouse cells 0.01474 
Immune response_Oncostatin M signaling via JAK-Stat in human cells 0.01636 
Regulation of lipid metabolism_FXR-dependent negative-feedback regulation of bile acids 
concentration 0.02527 
Cell adhesion_Plasmin signaling 0.02849 
Immune response_Oncostatin M signaling via MAPK in mouse cells 0.02849 
Immune response_Oncostatin M signaling via MAPK in human cells 0.03009 
HIV-1 signaling via CCR5 in macrophages and T lymphocytes 0.0317 
Transport_ACM3 in salivary glands 0.0341 
Immune response_IL-13 signaling via JAK-STAT 0.0357 
Immune response_MIF-induced cell adhesion, migration and angiogenesis 0.03729 
Development_GM-CSF signaling 0.04048 
Immune response_Histamine signaling in dendritic cells 0.04048 
Development_FGF-family signaling 0.04207 
Immune response_CCL2 signaling 0.04366 
Chemotaxis_CCL2-induced chemotaxis 0.04524 
Immune response_TREM1 signaling pathway 0.04762 
Triacylglycerol metabolism p.1 0.04762 
Immune response_IL-17 signaling pathways 0.04841 
Immune response_IL-18 signaling 0.04841 
Immune response_CD40 signaling 0.05235 
 
1.3.2 Personalized profiling identifies additional genes and functional pathways 
previously implicated in cancer 
Genes: For the personalized profiles, the gene expression data for each individual 
patient were analyzed identically to the group profiling analyses. The number of 
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significantly differentially expressed probe sets between cancer and normal replicate 
samples of each patient (p-value ≤ 0.005) varied up to  2-fold between patients (P1, 188 
probe sets; P2, 267 probe sets; P3, 435 probe sets; P4, 291 probe sets). The clustering of 
these differentially expressed probe sets for each patient is presented as heat maps in 
Figure 1.2.   
 
Figure 1.2. Supervised clustering of probe sets displaying a significant (p-value ≤ 0.005) difference in 
expression  between normal and cancer samples for patients P1 (a), P2 (b), P3 (c), and P4 (d). The heatmap 
was generated by z-score normalization of log2 expression values from the Affymetrix HG U133 Plus 2.0 
chip. Patients are denoted as P1, P2, P3, and P4 with their associated cancer and normal biological replicate 
samples (i.e., C1, C2, C3, and N1, N2, N3, respectively). 
 
A list of the 20 most significantly (p-value ≤ 0.005) differentially expressed genes 
ranked by fold change (10 most significantly up regulated and 10 most significantly 
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down regulated) between the normal and cancer samples for each individual patient are 
presented in Table 1.4 (a complete list of all significantly differentially expressed probe 
sets is presented in Tables A.1.1 and A.1.2).  
 
Table 1.4. The ten most significantly (p-value ≤ 0.005) up-regulated and ten most down-regulated genes  
between normal and cancer samples for each patient P1, P2, P3 and P4 from the personalized profiling 
analysis (Figure 1.2). 
 













205319_at PSCA 3.732981 0.000613 220576_at PGAP1 3.318862 0.001723 
226517_at BCAT1 2.959422 5.25E-05 217110_s_at MUC4 3.103023 3.01E-05 
1555294_a_at ERC1 2.923769 0.000932 220133_at ODAM 2.726326 0.003759 
226325_at ADSSL1 2.798377 0.001668 1567679_at SNORA74A 2.636617 0.001267 
228010_at PPP2R2C 2.667305 0.001297 201926_s_at CD55 2.627469 0.000945 
52255_s_at COL5A3 2.660518 0.001885 216504_s_at SLC39A8 2.436613 0.002912 
203877_at MMP11 2.417413 0.002271 238022_at CRNDE 2.275126 0.000994 
205534_at PCDH7 1.808023 0.002397 228962_at PDE4D 2.273621 0.002435 
207144_s_at CITED1 1.525835 0.003498 212768_s_at OLFM4 2.259513 0.000416 
241368_at PLIN5 1.471091 0.002259 205214_at STK17B 2.178595 0.003404 
1555236_a_at PGC -3.97182 0.000378 223761_at FGF19 -4.87686 0.000303 
219934_s_at SULT1E1 -3.25992 0.002483 207016_s_at ALDH1A2 -4.52882 0.004594 
223509_at CLDN2 -2.84658 0.000757 219106_s_at KBTBD10 -4.32228 0.001409 
226960_at CXCL17 -2.76824 0.001549 209277_at TFPI2 -4.17033 0.000529 
201236_s_at BTG2 -2.4767 0.005068 209993_at ABCB1 -4.04187 0.000584 
228912_at VIL1 -2.40512 0.001675 204965_at GC -3.8697 0.003231 
229254_at MFSD4 -2.23402 0.00422 234673_at HHLA2 -3.84065 3.20E-05 
243296_at NAMPT -2.20159 0.000229 222257_s_at ACE2 -3.54203 0.000581 
1562625_at FRYL -2.08383 0.005056 205380_at PDZK1 -3.37185 0.000588 
225283_at ARRDC4 -1.95739 0.003397 214397_at MBD2 -3.23842 0.004437 













204920_at CPS1 4.650319 0.000671 215867_x_at CA12 2.933468 0.00025 
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239196_at ANKRD22 4.62406 0.000438 208268_at ADAM28 2.429627 0.004945 
206291_at NTS 4.048737 0.003113 235155_at BDH2 1.938958 0.001707 
220639_at TM4SF20 3.977558 0.000243 229241_at LDHD 1.735299 0.002328 
218173_s_at WHSC1L1 3.895598 1.04E-05 206242_at TM4SF5 1.611106 0.000131 
209806_at HIST1H2BK 3.831179 0.003936 204602_at DKK1 1.53691 0.003798 
230252_at LPAR5 3.741123 0.001988 224224_s_at PDE11A 1.501315 0.001659 
40020_at CELSR3 3.695498 0.002774 1567079_at CLN6 1.498309 0.00314 
1557129_a_at FAM111B 3.592115 0.000226 236129_at GALNT5 1.434861 0.004932 
1556357_s_at ERICH1 3.544031 0.002244 219404_at EPS8L3 1.428246 0.00397 
214411_x_at CTRB2 -5.7882 0.000797 219179_at DACT1 -3.6374 0.001905 
211766_s_at PNLIPRP2 -5.52339 0.001025 213680_at KRT6B -3.3096 0.00037 
207802_at CRISP3 -5.49445 0.00027 206227_at CILP -2.94772 0.000918 
205971_s_at CTRB1///CTR
B2 
-5.42292 0.000386 204464_s_at EDNRA -2.86192 0.003475 
205886_at REG1B -5.25456 0.000635 1560224_at AHCTF1 -2.56906 0.000756 
205509_at CPB1 -5.24977 0.000438 226412_at SFRS18 -2.51134 0.00462 
209277_at TFPI2 -4.04264 0.005253 225571_at LIFR -2.43013 0.005276 
209616_s_at CES1 -3.88049 0.003005 201108_s_at THBS1 -2.42659 0.003524 
207254_at SLC15A1 -3.77115 0.000382 201838_s_at SUPT7L -2.42213 0.001748 
211738_x_at CELA3A -3.54389 0.004419 1563321_s_at MLLT10 -2.37822 0.004121 
 
Patient 1 (P1). A number of genes previously associated with cancer 
onset/progression were among the top 20 most significantly differentially expressed in 
the P1 cancer sample. Among the most significantly up-regulated genes in P1 was PSCA 
(prostate stem cell antigen) a gene implicated in pancreatic cancer [39]. Also up regulated 
were BCAT1 (branched chain amino-acid transaminase 1, cytosolic) and MMP11 (matrix 
metallopeptidase 11 (stromelysin 3)). Over expression of BCAT1 has been correlated with 
the clinical outcome of patients with breast cancer [40], colorectal cancer [41], 
neuroendocrine cancer [42] and melanoma [43]. Likewise, elevated MMP11 expression 
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has been previously associated with aggressiveness of many cancer types [44, 45] and the 
MMP11 protein has been proposed as a target antigen for cancer immunotherapy [46].  
Among the down-regulated genes in the P1 cancer sample were NAMPT, VIL1, 
BTG2, CXCL17, CLDN2, SULT1E1 and PGC. NAMPT (nicotinamide 
phosphoribosyltransferase) is known to play an important role in the regulation of insulin 
secretion of pancreatic  cells and it has been characterized as an immunomodulatory 
gene that regulates cell viability, inflammation and cancer [47, 48]. Loss of VIL1 (villin 
1) is a feature of poorly differentiated colorectal cancers [49]. BTG2 (BTG family, 
member 2), a p53-inducible anti-proliferative gene [50], has been reported to be absent in 
65% of human breast tumors [51]. Interestingly, loss of CXCL17 (chemokine (C-X-C 
motif) ligand 17) expression, as observed in P1, has been associated with progression 
from pancreatic adenoma to pancreatic adenocarcinoma [52]. The down-regulation of 
CLDN2 (claudin 2) in P1 is consistent with the fact that most of the claudins display 
reduced expression in most cancers [53]. Lack of expression of the sulfotransferase 
family 1E, estrogen-preferring, member 1 (SULT1E1), a gene encoding an enzyme that 
catalyzes the sulfate conjugation of many hormones, neurotransmitters, drugs, and 
xenobiotic compounds, has been reported to be down regulated in prostate and breast 
cancer tissues and cell lines [54]. Lastly, reduced expression of PGC (progastricsin) has 
been associated with stomach cancer [55, 56]. 
Patient 2 (P2). Among the genes uniquely over-expressed in the P2 cancer sample 
was ODAM (ondotogenic ameloblast-associated), a gene that has recently been identified 
as a biomarker for breast cancer [57]. Over-expression of CD55 (CD55 molecule, decay 
accelerating factor for complement (Cromer blood group)) has been associated with 
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prostate [58], breast [59], ovarian [60], and colorectal cancer [57]. Olfactomedin-4 
(OLFM4) is a novel anti-apoptotic gene that has been reported to promote proliferation of 
pancreatic tumor cells [61]. Among the genes significantly down regulated in the cancer 
tissue isolated from patient 2, was ALDH1A2 (aldehyde dehydrogenase 1 family, member 
A2). This gene has been identified as a tumor suppressor gene in prostate cancer [62]. 
ABCB1 (ATP-binding cassette, sub-family B (MDR/TAP), member 1), also down 
regulated in P2 cancer, belongs to a family of genes that modulate the absorption, 
metabolism, and toxicity of pharmacological agents [63]. Down-regulation of ACE2 
(angiotensin I converting enzyme (peptidyl-dipeptidase A) 2) has been identified as a 
tumor suppressor in pancreatic cancer [64]. 
Patient 3 (P3). Among the uniquely over-expressed genes in P3 cancer was 
neurotensin (NTS), a gene encoding a secreted peptide widely distributed throughout the 
central nervous system, and recently shown to regulate growth of pancreatic cancer cells 
[65, 66]. Another up-regulated gene, WHSC1L1 (Wolf-Hirschhorn syndrome candidate 1-
like 1), is known to play a fundamental role in chromatin organization and is over-
expressed in breast cancer [67, 68]. CELSR3 (cadherin, EGF LAG seven-pass G-type 
receptor 3), also over-expressed in P3 cancer, is believed to be involved in contact-
mediated communication (i.e., cell adhesions and ligand–receptor interactions) during 
cancer progression [69, 70]. Over-expression of ERICH1 (glutamate-rich 1) has been 
associated with higher copy number in pancreatic cancer [71].  
Among the uniquely down-regulated genes in P3 cancer, were CTRB2 
(chymotrypsinogen B2), CPB1 (carboxypeptidase B1 (tissue) and PNLIPRP2 (pancreatic 
lipase-related protein 2). Interestingly, over-expression of each of these genes has been 
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associated with poor-prognosis of pancreatic cancer patients [72]. The fact that these 
genes are down regulated in patient 3 may be related to this patient’s relatively positive 
clinical outcome (Table 1.1). Also significantly down regulated were two genes, CTRB1 
(chymotrypsinogen B1) and REG1B (regenerating isle-derived 1 beta) that have been 
previously reported to be down regulated in pancreatic cancers [73]. 
Patient 4 (P4): The two most significantly over-expressed genes in P4, CA12 and 
ADAM28, have been previously associated with tumor growth. The former, CA12 
(carbonic anydrase XII), has been hypothesized to maintain the acidic pH of tumors and 
therefore promote growth and invasion [74]. The latter, ADAM28 (ADAM 
metallopeptidase domain 28), belongs to a novel gene family and has been reported to be 
over expressed in many malignant tumors promoting tumor growth and invasion [75, 76]. 
Among the genes down regulated in P4 cancer is DACT1 and KRT6B.  DACT1 (dapper, 
antagonist of beta-catenin, homolog 1) plays an important role in stability of  catenin, 
and has been associated with colon cancer progression [77]. KRT6B (keratin 6B) encodes 
a basal-like cytokeratin that is aberrantly expressed in triple-negative breast cancer 
subtypes [78]. Of the remaining down-regulated genes, in P4 cancer is EDNRA 
(endothelin receptor type A), one of the endothelin receptors. There is recent evidence 
that down regulation of endothelin signaling results in cell survival alterations, cell 
invasiveness and carcinogenesis of various cancer types [79-81]. 
Pathways: As in the group analysis, functional pathway analysis was carried out 
on all significantly (p-value ≤ 0.005) differentially expressed, unique, annotated genes for 
each patient (P1, 148 genes; P2, 211 genes; P3, 351 genes; P4, 215 genes) to identify 
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functional pathways significantly overrepresented (p ≤ 0.05) in the cancer samples 
isolated from each individual patient (Table 1.5). 
 
Table 1.5. The significantly enriched pathways (p ≤ 0.05) of the annotated, unique, differentially expressed 
genes in P1 (148 genes, 15 pathways), P2 (211 genes, 17 pathways), P3 (351 genes, 25 pathways) and P4 
(215 genes, 30 pathways). 
P1 Pathway Maps p-Value P2 Pathway Maps p-Value 
Immune response_NFAT in immune response 0.001482 Development_Notch Signaling Pathway 0.0004555 
Immune response_CD28 signaling 0.001942 Transcription_Sin3 and NuRD in transcription regulation 0.003978 
Cell adhesion_Tight junctions 0.01115 Cell cycle_Nucleocytoplasmic transport of CDK/Cyclins 0.006032 
Immune response_TCR and CD28 co-stimulation in 
activation of NF-kB 0.01365 
Development_Ligand-independent activation of ESR1 and 
ESR2 0.006414 
Neurophysiological process_Glutamate regulation of 
Dopamine D1A receptor signaling 0.01708 Cytoskeleton remodeling_Integrin outside-in signaling 0.00813 
Signal transduction_PKA signaling 0.02163 Signal transduction_PKA signaling 0.00908 
Cell adhesion_ECM remodeling 0.02244 
Development_Thrombopoetin signaling via JAK-STAT 
pathway 0.01466 
Immune response_T cell receptor signaling pathway 0.02325 
Cell adhesion_Endothelial cell contacts by non-junctional 
mechanisms 0.01732 
Immune response_Immunological synapse formation 0.02839 Cell cycle_Regulation of G1/S transition (part 2) 0.02018 
Glutathione metabolism 0.03299 
Neurophysiological process_GABA-B receptor signaling at 
postsynaptic sides of synapses 0.02018 
Cardiac Hypertrophy_NF-AT signaling in Cardiac 
Hypertrophy 0.03394 
Immune response_Innate immune response to RNA viral 
infection 0.02322 
Glutathione metabolism / Human version 0.03394 Chemotaxis_Leukocyte chemotaxis 0.0255 
Glutathione metabolism / Rodent version 0.03886 LRRK2 in neurons in Parkinson's disease 0.03156 
Chemotaxis_Leukocyte chemotaxis 0.04404 G-protein signaling_RhoA regulation pathway 0.03335 
Development_Role of nicotinamide in G-CSF-
induced granulopoiesis 0.05239 Cell adhesion_Plasmin signaling 0.03519 
  Cell cycle_Regulation of G1/S transition (part 1) 0.04091 
  Cell adhesion_Chemokines and adhesion 0.05265 
P3 Pathway Maps p-Value P4 Pathway Maps p-Value 
 19 
“Table continued” 
Cell cycle_Chromosome condensation in 
prometaphase 4.77E-06 Development_WNT signaling pathway. Part 2 0.00002776 
Cell cycle_Spindle assembly and chromosome 
separation 0.000708 Apoptosis and survival_p53-dependent apoptosis 0.000972 
Cell cycle_Transition and termination of DNA 
replication 0.004926 
Mechanisms of CFTR activation by S-nitrosoglutathione 
(normal and CF) 0.00372 
Proteolysis_Putative SUMO-1 pathway 0.005445 Cell cycle_Nucleocytoplasmic transport of CDK/Cyclins 0.003952 
Cell cycle_Role of APC in cell cycle regulation 0.007195 
Mechanism of Pioglitazone/ Metformin and Rosiglitazone/ 
Metformin  cooperative action in Diabetes mellitus, Type 2 0.005167 
Androstenedione and testosterone biosynthesis and 
metabolism p.2 0.009241 Cell cycle_Role of 14-3-3 proteins in cell cycle regulation 0.009688 
Cell cycle_The metaphase checkpoint 0.009991 
DNA damage_ATM / ATR regulation of G2 / M 
checkpoint 0.0134 
Androstenedione and testosterone biosynthesis and 
metabolism p.2/ Rodent version 0.009991 Cell cycle_Transition and termination of DNA replication 0.01544 
Immune response_IL-12-induced IFN-gamma 
production 0.009991 Development_Thrombospondin-1 signaling 0.01544 
Transcription_Role of AP-1 in regulation of cellular 
metabolism 0.0116 DNA damage_Role of Brca1 and Brca2 in DNA repair 0.01762 
Cell cycle_Nucleocytoplasmic transport of 
CDK/Cyclins 0.01272 Cell cycle_Role of APC in cell cycle regulation 0.01992 
Transport_RAN regulation pathway 0.0207 LRRK2 in neurons in Parkinson's disease 0.02111 
Cell cycle_Sister chromatid cohesion 0.03027 Cell cycle_Spindle assembly and chromosome separation 0.02111 
Immune response_IL-12 signaling pathway 0.03289 
Apoptosis and survival_Cytoplasmic/mitochondrial 
transport of proapoptotic proteins Bid, Bmf and Bim 0.02233 
Glycolysis and gluconeogenesis p.3 / Human version 0.03559 Estradiol metabolism 0.02358 
Glycolysis and gluconeogenesis p.3 0.03559 Estrone metabolism 0.02358 
Cell cycle_Initiation of mitosis 0.03837 Estradiol metabolism / Human version 0.02486 
Immune response_IL-23 signaling pathway 0.03837 Estrone metabolism / Human version 0.02486 
DNA damage_ATM / ATR regulation of G2 / M 
checkpoint 0.04124 Estradiol metabolism / Rodent version 0.02617 
Glutathione metabolism / Human version 0.04722 Cell cycle_Regulation of G1/S transition (part 1) 0.0275 
Glycolysis and gluconeogenesis (short map) 0.04904 Cell adhesion_Chemokines and adhesion 0.0306 
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Cell cycle_Role of SCF complex in cell cycle 
regulation 0.0503 Apoptosis and survival_BAD phosphorylation 0.03311 
Apoptosis and survival_p53-dependent apoptosis 0.0503 Signal transduction_AKT signaling 0.03457 
Apoptosis and survival_Granzyme A signaling 0.05346 Apoptosis and survival_FAS signaling cascades 0.03606 
Cytoskeleton remodeling_RalA regulation pathway 0.05346 Development_Adiponectin signaling 0.03758 
  
Cytoskeleton remodeling_TGF, WNT and cytoskeletal 
remodeling 0.03985 
  NAC-AsPC-1 0.04682 
  NAC-AsPC-1 0.04682 
  Untitled 0.04682 
  Some pathways of EMT in cancer cells 0.04716 
 
Patient 1 (P1). Five of the 15 most significantly enriched pathways in P1 are 
associated with the immune response. More specifically, NFAT (nuclear factor of 
activated T cells) is a major transcriptional regulator in T cells and recently identified as a 
potent immuno-regulator in cancer development and as a potential target for therapeutic 
manipulation of the immune response in cancer patients [82]. P1 also showed enrichment 
for the TCR and CD28 signaling pathways. Glutathione metabolism was also identified 
as a significantly enriched pathway in P1. Glutathione is known to affect the efficacy of 
anti-neoplastic interventions mainly through nucleophilic thioether formation or 
oxidation-reduction reactions [83]. The prevalence of enriched immune response and 
glutathione metabolism pathways may help account, thus far, for the favorable outcome 
in patient P1 (Table 1.1).  
   Patient 2 (P2). Patient P2 displayed pathways that have been implicated strongly 
in cancer development and invasion. Notch signaling participates in many developmental 
processes regulating cell differentiation, proliferation, apoptosis, adhesion, epithelial-to-
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mesenchymal transition, migration, angiogenesis, and can act either as an oncogene or 
tumor suppressor in a highly context-dependent manner [84]. Cell-cycle disruption is a 
typical feature of cancer cells and results in DNA damage [85]. Cytoskeleton remodeling 
is required for cancer cell invasion and metastasis, apparent in most cancers [86]. Cell 
adhesion determines the polarity of cells and maintains the cell architecture in tissues. 
Cell adhesiveness is generally reduced in cancer to allow for invasiveness, extra cellular 
matrix decomposition and metastasis [87].  
Patient 3 (P3). Genes in patient P3 were enriched predominantly for cell cycle 
regulatory pathways (nine out of a total 25 pathways). This is typical for cancer cells at 
an advanced stage as with patient P2. Like patient P1, P3 showed enrichment of 
interleukin-mediated immune responses, and the glutathione metabolism pathway. 
Interleukin-12 (IL-12) is a powerful coordinator of the innate and adaptive immune 
responses and has been shown to have promising anti-tumor effects in murine tumor 
models [88]. IL-12 is currently being investigated as a potential therapeutic agent against 
cancer [89]. 
Patient 4 (P4). The most significantly enriched pathway in P4 was the WNT 
-catenin pathway has emerged as a critical 
regulator in stem cells and has also been associated with cancer in many tissues [90]. For 
P4, this particular WNT pathway, involved the frizzled family receptor 7 (FZD7), which 
was up regulated. Up regulation of FZD7 has been reported in gastric and colorectal 
cancers [91, 92]. P4 also showed enrichment of apoptotic and survival pathways. In the 
p53 dependent apoptosis pathway, the BCL2L11 gene (BCL2-like 11-apoptosis 
facilitator), responsible for cytoplasmic transport of proapoptotic proteins BID, BMF and 
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BIM, is down regulated. On the other hand, CDK1 (cyclin-dependent kinase 1) that 
promotes phosphorylation of the proapoptotic BAD (BCL-2-associated agonist of cell 
death) was up regulated in the BAD phosphorylation pathway. This is evidence for de-
regulation of the apoptosis and survival pathways in patient P4. 
 
1.3.3 Significant genes and pathways in the personalized analyses display little to no 
overlap among individual patients or with those identified in the group analysis 
As shown above, both the group and the personalized analyses identified genes 
and pathways previously implicated in the onset/progression of pancreatic and a broad 
spectrum of other cancers. We were next interested in determining the degree of overlap 
among those genes and pathways identified as significant in each of the individual patient 
analyses and in the group analysis. Interestingly, we found that the degree of overlap is 
remarkably low. As shown in Figure 1.3 (see also Tables A.1.1 and A.1.2), less than 
6.5% (average 3.3%) of the genes identified as significantly differentially expressed 
between normal and cancer cells isolated from individual patients (personalized profiles) 
overlap with genes identified as significantly differentially expressed across the 
combined patient samples (group analysis).  Likewise, there is remarkably little overlap 
among the individual patients.  For example, of the combined number of annotated genes 
identified as significantly differentially expressed in samples P1 and P2 (148 + 211 = 
359), there was less than 1% (2/359 ≈ 0.006) overlap. Even between P2 and P3, samples 
that share the largest number of overlapping genes (8 genes), the degree of overlap is 
only slightly more than 1%   (8/(211+351) ≈ 0.014). 
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  Group P1 P2 P3 P4 
Group - 4 31 30 7 
P1   - 2 4 2 
P2     - 8 3 
P3       - 4 
P4         - 
 
Figure 1.3. Venn diagrams and table showing the unique, annotated genes identified as significantly 
differentially expressed in the group analysis and in the personalized analysis(es) of at least one patient.  
 
Comparison of the most significantly over-represented pathways identified in the 
personalized and group analyses resulted in similar results to the gene analyses, i.e., there 
is relatively little overlap between pathways identified as over-represented in the group 
analysis vs. the personalized analyses. Furthermore, there is remarkably little overlap in 
over-represented pathways among individual patients based on the personalized profiles 




  Group P1 P2 P3 P4 
Group - 0 1 2 0 
P1   - 2 1 0 
P2     - 1 4 
P3       - 6 
P4         - 
 
Figure 1.4. Venn diagrams and table showing pathways identified as significantly enriched in the group 
analysis and in the personalized analysis(es) of at least one patient.  
 
As shown in Figure 1.4 (see also Table A.1.3), less than 5% (average 1.7%) of the 
pathways identified as significantly over-represented in individual patients (personalized 
profiles) overlap with pathways of genes identified as significantly differentially 
expressed across the combined patient samples (group analysis).  In fact, pathways 
identified as over-represented in two of the patient samples (P1 and P4), had no overlap 
with those identified in the group analysis. Additionally, there is relatively little overlap 
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among the individual patients.  For example, of the pathways identified as significantly 
over-represented in samples P1 and P2 (15 + 17 = 32), there was only 6.3% (2/32 ≈ 
0.063) overlap. Even between P3 and P4, samples that share the largest number of 
significantly over-represented pathways (6 pathways), the degree of overlap is less than 
11%   (6/(25 + 30) ≈ 0.109).  
The results of the above studies indicate that genes and pathways identified as 
being most significantly different between normal and cancer samples as determined by 
the group analysis display little or no overlap with those identified as significant by 
individual personalized analyses. Likewise, we found little or no overlap in genes and 
pathways identified as being most significantly different among individual patient 
samples (personalized analyses). To address the possibility that these findings may 
simply be an artifact of the relatively small number of patients examined in our study, we 
conducted a similar analysis using data from a previously published microarray gene 
expression analysis of control and cancer tissue samples isolated from 36 patients [15].  
In this earlier study, replicate assays were carried out on three patients allowing us to 
compare the most significantly differentiated genes as determined by a group analysis (36 
patient samples) vs. the significantly differentiated genes determined in personalized 
analyses of three patients. Consistent with our previous findings, the results demonstrate 
remarkably little overlap between genes identified as significant in the group vs. 
personalized analyses (Figure 1.5, Table A.1.4).  
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  Group P5 P6 P7 
Group - 3 5 3 
P5   - 0 0 
P6     - 0 
P7       - 
 
Figure 1.5. Venn diagrams and table showing the genes identified as significantly differentially expressed 
in the group analysis and in the personalized analysis(es) of at least one patient (data from Badea et. al.).  
 
As shown in Figure 1.5 (see also Table A.1.4), less than 2% (average 1.07%) of 
the genes identified as significantly differentially expressed between normal and cancer 
cells (p ≤ 0.00001) isolated from individual patients (personalized profiles) overlap with 
genes identified as most significantly differentially expressed (top 500 of 17,658 genes 
significantly differentially expressed, p ≤ 0.00001) across the combined patient samples. 




Molecular profiling is revolutionizing the way we view and treat cancer. Rather 
than the traditional tissue-of-origin approach to the classification and treatment of the 
disease, molecular profiling is providing gene-based diagnostics and therapeutics as a 
realistic alternative. The identification of key genes/pathways associated with various 
types of cancer is the foundation for both molecular diagnostics and therapeutics.  
The group approach to the identification of key genes/pathways involves combining the 
molecular profiles of collections of samples from diseased patients in order to identify 
shared variant profiles that are distinct from those associated with non-diseased controls 
(e.g., [93]) .  While this can be a productive approach for the detection of biomarkers and 
potential therapeutic targets for diseases caused by one or a few genes, for diseases 
caused by aberrations in a variety of alternative genes/pathways, the group approach may 
be less effective [94].  
Initial sequence analyses of tumor samples isolated from a large number of cancer 
patients suggest that, from the molecular perspective, pancreatic cancer may be a highly 
heterogeneous disease [13]. In the present study, we were interested in further examining 
this question by comparing the most significantly differentially expressed 
genes/pathways between pancreatic cancer and control samples as determined by group 
vs. personalized analyses of the same samples.  Toward this end, we employed LCM to 
collect three distinct sets (biological replicates) of normal and cancer cells from tissue 
samples obtained from four pancreatic patients.  In addition, we re-analyzed data from a 
previous gene expression analysis of 36 pancreatic patients [15] and compared the most 
significantly differentiated genes/pathways as determined by the group analysis relative 
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to the most significantly differentiated genes/pathways as determined by personalized 
analyses of three patients for which replicate microarray assays were performed.   
Our results consistently demonstrated little to no overlap between genes/pathways 
identified in the group analyses relative to those identified in the personalized analyses. 
For example, consistent with earlier reports [95], our group analysis identified MUC4 as 
one of the most significantly differentiated expressed genes between the normal and 
pancreatic cancer samples (Table 1.2). Indeed, MUC4 has recently been proposed as a 
prime candidate for targeted drug therapy in pancreatic cancer [20]. In our personalized 
analyses, however, MUC4 was identified as significantly over-expressed in only 1 of the 
7 patients examined suggesting that MUC4 therapy would likely not be effective for the 
majority of the patients examined in our study.  Conversely, many of the genes identified 
as being significantly differentially expressed in individual patients (personalized 
profiles) were not identified as significant in the group analysis. For example, the most 
significantly differentially expressed gene in the cancer samples isolated from patient 1 is 
PSCA (prostate stem cell antigen). Interestingly, a monoclonal antibody against PSCA is 
currently being tested in clinical trials for both prostate and pancreatic cancer [96, 97]. 
Thus, while PSCA targeted therapy might well be expected to be effective for patient 1, it 
was not identified as being significantly over-expressed in the group analysis nor in the 
personalized analyses of any of the other patients examined. Similarly, ADAM (a 
disintegrin and metalloprotease), a gene reported to be over-expressed in a number of 
human cancers [75] and identified as a potential candidate for targeted gene therapy [98], 
was among the most significantly over-expressed genes in patient 4 but was not identified 
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as being significantly over-expressed in the group analysis nor in the personalized 
analyses of any of the other patients examined.  
Collectively, our results are consistent with earlier findings indicating that, on the 
molecular level, pancreatic cancer is a highly heterogeneous disease [13]. While targeted 
gene therapy holds great promise in the treatment of pancreatic and other cancers, a 
crucial step in the process is the accurate identification of appropriate candidate genes for 
targeted therapy. Our findings indicate that personalized and not group molecular 
profiling is the most appropriate approach for the identification of putative candidates for 
effective targeted gene therapy for pancreatic and perhaps other cancers with 
heterogeneous molecular etiology.  
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MOLECULAR PROFILING PREDICTS THE EXISTENCE OF TWO 
FUNCTIONALLY DISTINCT CLASSES OF OVARIAN CANCER 
STROMA 
2.1 Introduction 
The epithelial cells of the ovary interact with the cells of the surrounding 
microenvironment in order to regulate tissue homeostasis. Morphologically, the normal 
ovarian epithelial cells form a flat-to-cuboidal monolayer supported by a basement 
membrane. Cells located below this basement membrane are composed of various cell 
types collectively referred to as stromal cells. The most common types of stromal cells 
are fibroblasts, pericytes, endothelial cells, and various immune and inflammatory cells. 
Stromal and epithelial cells communicate through the secretion and binding of growth 
factors and other signaling molecules that promote reciprocal cellular responses 
appropriate for coordinated cell functions, for example, those required for the replication 
of ovarian surface epithelial cells following ovulation [1-3].  
During cancer progression, genetic and epigenetic alterations lead to changes in 
the morphology and behavior of both epithelial and stromal cells by disrupting the tissue 
architecture and by interfering with signaling mechanisms. For example, signaling 
changes in a wide variety of developing cancer cells have been shown to result in the 
disruption of tissue homeostasis by inducing extracellular matrix (ECM) turnover, 
basement membrane disassociation, and increased stromal cell proliferation [1, 4].  
 Despite the well-documented role of stromal cell signaling in cancer progression, 
relatively few studies have been focused specifically on epithelial ovarian cancer-stromal 
interactions (EOC-SI). Previously reported studies on EOC-SI have focused on particular 
stromal components [5, 6], on specific cell lines [7] and/or employed in-house fabricated 
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microarrays of limited scope [8]. We report here the results of a study of EOC-SI using 
high-throughput gene expression (microarray) analysis of normal ovarian surface 
epithelial cells and cells captured from normal stroma, cancer epithelia, and cancer 
stroma using laser capture microdissection (LCM). Our results reveal the existence of 
two categories of ovarian cancer stroma. Analysis of ligand-receptor patterns of gene 
expression indicates that one of these classes of cancer stroma may be more permissive 
and one more resistant to associated cancer cell growth.  
 
2.2 Materials and Methods 
2.2.1 Tissue collection 
Tissues were collected at Northside Hospital (Atlanta, GA) under appropriate 
Institutional Review Board protocols. Following resection, the tumor tissues were placed 
in cryotubes and immediately (<1 minute) frozen in liquid nitrogen. Samples were 
transported on dry ice to Georgia Institute of Technology (Atlanta, GA), and stored at -80 
ºC.  All tissues were examined and diagnoses made by a pathologist. The histopathology 
for each sample is listed in Table 2.1.  
 
Table 2.1. Patient samples used in this study 
Patient ID 




Histopathology Stage Grade 
460 65 OSE WNL(Within Normal Limits) N/A N/A 
552 41 OSE WNL N/A N/A 
563 66 OSE                   WNL N/A N/A 
567 78 OSE WNL N/A N/A 
434 41 OSE/NS WNL N/A N/A 
437 54 OSE/NS WNL N/A N/A 
440 50 OSE/NS WNL N/A N/A 
448 63 OSE/NS WNL N/A N/A 
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“Table continued” 
452 51 OSE/NS WNL N/A N/A 
463 48 OSE/NS WNL N/A N/A 
470 44 OSE/NS WNL N/A N/A 
475 63 OSE/NS WNL N/A N/A 
317 59 Cepi serous adenocarcinoma Ic 3 
489 48 Cepi serous adenocarcinoma IV 3 
528 66 Cepi serous adenocarcinoma IIIc 3 
537 64 Cepi serous adenocarcinoma IIIa 2 
542 61 Cepi serous adenocarcinoma IV 3 




588 71 Cepi serous adenocarcinoma IIIc 2 
606 54 Cepi serous adenocarcinoma IIIa 3 
617 64 Cepi serous adenocarcinoma IIIc 2 
620 62 Cepi serous adenocarcinoma III/IV 3 




183 66 Cepi/CS serous adenocarcinoma III 2 
369 52 Cepi/CS serous adenocarcinoma IIIc 2 
229 58 Cepi/CS serous adenocarcinoma IIIc 3 
242 63 Cepi/CS serous adenocarcinoma IIIb 3 
336 63 Cepi/CS serous adenocarcinoma Ic 3 
367 56 Cepi/CS serous adenocarcinoma II 3 
413 49 Cepi/CS serous adenocarcinoma IIb 3 
 
 For each of the cancer tissue samples, m frozen sections were cut from samples 
embedded in cryomatrix (Shandon), and attached to uncharged microscope slides.  
Immediately following dehydration and staining (HistoGene, LCM Frozen Section 
Staining Kit, Arcturus), slides were processed in an Autopix (Arcturus) instrument for 
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laser capture microdissection (LCM) of cancer epithelial cells (Cepi), cancer stroma 
(CS), and normal stroma (NS) using CapSure Macro-LCM Caps (Arcturus). 
Approximately 30,000 cells were collected from each of the samples. Normal 
ovarian surface epithelial (OSE) cells were also collected from normal ovaries at the time 
of surgery by light brushing using a Cytobrush Plus (Medscand), immediately stabilized 
in RNAlater (Ambion), and subsequently stored at -20 ºC. Microscopic examination of 
all collected cells was carried out to confirm the integrity and purity of the samples.   
 
2.2.2 RNA extraction and amplification 
PicoPure RNA Isolation Kit (Arcturus) protocols were followed for RNA 
extraction from the LCM cells on the Macro-LCM caps in 25µL of extraction buffer.  
Normal OSE cells were pelleted from RNAlater, RNA was isolated with Trizol 
(Invitrogen), and purified with the PicoPure RNA Isolation Kit. RNA quality was verified 
for all samples on the Bioanalyzer RNA Pico Chip (Agilent Technologies). 
 Total RNA from the above extractions was processed using the RiboAmp HS kit 
(Arcturus) in conjunction with the IVT Labeling Kit from Affymetrix, to produce an 
amplified, biotin-labeled mRNA suitable for hybridizing to GeneChip Human Genome 
U133 Plus 2.0 Arrays (Affymetrix) following manufacturer's recommendations. 
 
2.2.3 Microarray data analysis 
We generated 45 individual gene expression profiles from 12 OSE brushings and 
18 Cepi, 8 NS and 7 CS patient samples isolated by laser capture microdissection (LCM). 
Affymetrix .CEL files were processed using the Affymetrix Expression Console (EC) 
Software Version 1.1 with the default MAS5.0 probeset normalization algorithm. The 
expression values from the 12 OSE, 18 Cepi, 8 NS and 7 CS samples were log2 
transformed and then averaged for each probeset across each sample type. The 
microarray data were deposited in the Gene Expression Omnibus (GSE38666). 
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Probesets (genes) with nearly constant expression values (log2 normalized) across 
samples (SD < 1) were excluded from further consideration. Of the 54,675 probesets on 
the U133 Plus 2.0 chip, 42,698 were thus retained. A four-way ANOVA was 
subsequently employed to identify genes significantly differentially expressed (p≤0.001) 
across the four sample groups (OSE, Cepi, NS and CS). These 6,654 genes were 
employed in the initial clustering analysis.  
A subsequent comparison among the CS samples (CS1 & CS2) alone was 
performed using a similar approach. Specifically, genes with nearly identical expression 
values (SD<1) across CS1 & CS2  were discarded and the remaining 38,972 genes were 
subjected to an unpaired t-test to identify those genes that were significantly differentially 
expressed between the CS1 & CS2 sub-groups (p≤0.001, 88 genes). 
All heat maps were generated using the UPGMA (unweighted average) clustering 
method and the Euclidean distance similarity measure.  
 
2.2.4 Ligand-receptor compatibility analysis 
For the ligand-receptor compatibility analysis, probesets associated with no or 
marginal expression across all 45 samples were discarded resulting in 5,865 differentially 
expressed genes. The presence or absence of the expression in samples was determined 
using the Affymetrix default MAS 5.0 decision algorithm. The MAS 5.0 algorithm uses 
the Tukey's biweight estimator to provide a robust mean signal value and the Wilcoxon's 
rank test to calculate the significance of the signal or p-value and detection call (present, 
marginal or absent) for each probeset. The p-values upon which the presence-absence 
calls for each ligand and receptor is based are presented in the appropriate tables (below).  
 
2.3 Results 
2.3.1 Hierarchical clustering establishes two distinct classes of stroma among the ovarian 
cancer patient samples 
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Forty-five gene expression profiles were generated from 12 OSE brushings and 
18 Cepi, 8 NS and 7 CS patient samples isolated by laser capture microdissection (LCM). 
The relevant histopathologies of these 45 samples are listed in Table 2.1. Expression 
analysis yielded 6,654 differentially expressed probesets among the four sample types 
(ANOVA, p ≤ 0.001). Hierarchical clustering of these expression data resulted in clear 
separations between the OSE, Cepi, NS and CS samples (Figure 2.1). Interestingly, the 
CS samples sub-divided into two distinct groups. One (CS1) was more closely associated 
with the NS samples and the other (CS2) was more closely associated with the Cepi 
samples.  
 
Figure 2.1. Hierarchical clustering of OSE, Cepi, NS and CS expression profiles. The heat map was 
generated by Z-score normalization of log2 expression values from Affymetrix HG U133 Plus 2.0. The 
results show that the OSE, Cepi, NS, and CS samples cluster into separate groups. The CS samples 
clustered into two distinct sub-groups (CS1 and CS2). 
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One possibility is that the two sub-classes of CS are simply a reflection of 
differential responses of stroma to molecular differences in the adjacent Cepi. If this were 
the case, we would expect to see a correlated sub-structure among the molecular profiles 
of the Cepi samples associated with the CS1 and CS2 sub-groups. As shown in Figure 2.1, 
no such coordinated sub-structure pattern exists among the Cepi samples indicating that 
the two sub-classes of CS are not merely a reflection of differential responses of the 
stroma to different Cepi sub-types. 
As stated above, microscopic examination of LCM collected cells was carried out 
to validate the integrity of our samples. As a further confirmation, we conducted an 
additional computational analysis. In this analysis, probesets associated with no or 
marginal expression across all 45 samples were discarded resulting in 5,865 differentially 
expressed genes. If the reason for the presence of two classes of CS samples is that the 
CS2 class was a mixture of stroma and invasive Cepi cells, the gene expression levels in 
the putative mixed cancer stromal class (CS2) would be expected to lie within the range 
of the maximum and minimum expression levels of the NS and Cepi groups (i.e., 
MaxCSavgMinCSavg  )(  and  )( 22 ). Inconsistent with this prediction, we found that 
2,342 or 40% (2,342/5,865) of the differentially expressed genes making up the CS2 class 
displayed values outside the predicted range of the mixed cell types. The fact that 60% of 
the expression values lie within the predicted range is not indicative of contamination but 
rather of the fact that not all genes are significantly over-expressed in the stroma relative 
to cancer samples. Collectively our microarray results are consistent with the microscopic 
examination in demonstrating the absence of infiltrating Cepi cells in the cancer stroma 
samples.  
 
2.3.2 Gene expression patterns are consistent with the existence of ligand-receptor 
interactions between Cepi and CS 
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The significance of the presence of two distinct classes of ovarian cancer stroma 
may involve differential interaction between these stroma and the adjacent cancer cells. 
To explore this possibility, we first examined the expression levels of genes encoding 
signaling ligands and compatible receptors in the CS and Cepi datasets.  
 Two lists were established from the 5,865 differentially expressed probesets 
across the OSE, Cepi, NS and CS samples. One list is comprised of all differentially 
expressed gene probes (note that each gene may be represented by multiple, non-
overlapping probes) encoding secreted ligands (ligand-list), and the other all expressed 
gene probes encoding surface receptors (receptor-list) with documented binding affinity 
to the differentially expressed ligands (compatible ligands and receptors). The ligand-list 
consists of 34 CS and 36 Cepi ligands while the receptor-list is comprised of 20 Cepi and 
21 CS receptors (Tables 2.2a and 2.2b). 
 
Table 2.2. The 34 CS expressed ligands with the 20 expressed Cepi receptors (2a) and the 36 Cepi 
expressed ligands with the 21 expressed CS receptors (2b) (Significance of detection calls: *p ≤ 0.05,
 
**p ≤ 
0.005, *** p ≤ 0.0005). 
(a)                                                                              (b) 
CS Ligands Cepi Receptors Cepi Ligands CS Receptors 
Gene Symbol Probeset ID Gene Symbol Probeset ID Gene Symbol Probeset ID Gene Symbol Probeset ID 
***CXCL1 204470_at ****CXCR4 217028_at ***CXCL1 204470_at ****CXCR4 217028_at 
*CXCL3 207850_at **FGFR2 208228_s_at **CXCL3 207850_at **FGFR2 208228_s_at 
***CXCL9 203915_at ***FGFR3 204379_s_at ***CXCL9 203915_at *FGFR3 204379_s_at 
***CXCL10 204533_at **MET 203510_at ***CXCL10 204533_at IL12RB1 1552584_at 
***CXCL11 210163_at *TGFBR2 207334_s_at ***CXCL11 210163_at ***IL1R1 202948_at 
***CXCL12 209687_at ***TGFBR2 208944_at *CXCL12 203666_at ***TGFBR2 208944_at 
***CXCL12 203666_at **TGFBR3 204731_at *CXCL12 209687_at ***TGFBR3 204731_at 
***CXCL13 205242_at ***TGFBR3 226625_at **CXCL13 205242_at ***TGFBR3 226625_at 
**CXCL16 223454_at ***PDGFRA 203131_at **CXCL16 223454_at ***PDGFRA 203131_at 
CXCL17 226960_at *PDGFRA 1554828_at CXCL17 226960_at **PDGFRA 215305_at 
*FGF1 205117_at ***IL1R1 202948_at *FGF1 205117_at ***MET 203510_at 
*FGF2 204422_s_at *IL1R1 215561_s_at ***FGF9 206404_at **IL1R1 215561_s_at 
***FGF7 1554741_s_at *IL1R2 205403_at ***FGF9 239178_at *IL1R2 205403_at 




**FGF9 206404_at **IL10RA 204912_at ***FGF18 231382_at **IL10RA 204912_at 
***FGF13 205110_s_at **FZD1 204451_at *FGF18 211029_x_at *IL21R 221658_s_at 
*HGF 210997_at **FZD2 210220_at *FGF18 206987_x_at **FZD1 204451_at 
***IGF1 209540_at **FZD7 203705_s_at **FGF18 214284_s_at **FZD2 210220_at 
*IGF2 202409_at ***FZD7 203706_s_at **TGFA 205016_at ***FZD7 203705_s_at 
*TGFA 205016_at **FZD10 219764_at **TGFB2 209909_s_at **FZD7 203706_s_at 
***TGFB2 209909_s_at    **PDGFA 205463_s_at ***FZD10 219764_at 
*PDGFA 205463_s_at    ***PDGFD 219304_s_at   
***PDGFD 219304_s_at    ***IGF1 209540_at   
*IL7 206693_at    *IL7 206693_at   
***IL15 205992_s_at    *IL1B 39402_at   
**IL16 209828_s_at    ***IL15 205992_s_at   
**IL17D 227401_at    **IL18 206295_at   
**IL18 206295_at    **WNT2 205648_at   
**WNT2B 206458_s_at    **WNT2B 206458_s_at   
*WNT7A 210248_at    ***WNT5A 213425_at   
***WNT5A 213425_at    *WNT7A 210248_at   
***VEGFA 210512_s_at    **WNT11 206737_at   
*VEGFA 210513_s_at    ***VEGFA 210512_s_at   
*VEGFA 211527_x_at    ***VEGFA 210513_s_at   
     *VEGFA 211527_x_at   
        **VEGFA 212171_x_at     
 
 We considered the expression of a ligand in CS (or Cepi) and its compatible 
receptor in Cepi (or CS) to be indicative of a potential CS-Cepi signaling interaction. 
Based on these criteria, we identified potential epithelial cancer-stroma signaling 
interactions (34 CS ligands and 20 Cepi receptors, see Table 2.2a, and 36 Cepi ligands 
and 21 CS receptors, see Table 2.2b). Of these, there were 17 compatible pairs for both 






Table 2.3. The expressed, compatible ligands and receptors as potential interactions between the Cepi and 
the CS samples from Tables 2.2a and 2.2b (significance of detection calls *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 
0.0005).  
(a)                                                                                     (b) 












***CXCL12 203666_at ***CXCR4 217028_at *CXCL12 203666_at ***CXCR4 217028_at 
***CXCL12 209687_at ***CXCR4 217028_at *CXCL12 209687_at ***CXCR4 217028_at 
*FGF1 205117_at **FGFR2 208228_s_at *FGF1 205117_at **FGFR2 208228_s_at 
*FGF1 205117_at *FGFR3 204379_s_at *FGF1 205117_at *FGFR3 204379_s_at 
*FGF2 204422_s_at *FGFR3 204379_s_at *FGF9 206404_at *FGFR3 204379_s_at 
**FGF9 206404_at *FGFR3 204379_s_at FGF9 239178_at *FGFR3 204379_s_at 
*FGF9 239178_at *FGFR3 204379_s_at *PDGFA 205463_s_at ***PDGFRA 203131_at 
*HGF 210997_at *MET 203510_at *PDGFA 205463_s_at *PDGFRA 215305_at 
*PDGFA 205463_s_at *PDGFRA 1554828_at *TGFB2 209909_s_at ***TGFBR2 208944_at 
*PDGFA 205463_s_at ***PDGFRA 203131_at *WNT2 205648_at *FZD2 210220_at 
***TGFB2 209909_s_at *TGFBR2 207334_s_at *WNT2B 206458_s_at ***FZD10 219764_at 
***TGFB2 209909_s_at ***TGFBR2 208944_at *WNT7A 210248_at ***FZD7 203705_s_at 
*WNT2 205648_at *FZD2 210220_at *WNT7A 210248_at **FZD7 203706_s_at 
**WNT2B 206458_s_at *FZD10 219764_at *IL1B 39402_at ***IL1R1 202948_at 
*WNT7A 210248_at *FZD7 203705_s_at *IL1B 39402_at *IL1R2 205403_at 
*WNT7A 210248_at **FZD7 203706_s_at *IL1B 39402_at *IL1R1 215561_s_at 
*IL7 206693_at **IL7R 226218_at *IL7 206693_at *IL7R 226218_at 
 
Viewed from the perspective of individual genes (i.e., combining multiple probes 
of the same genes) there were 12 unique CS ligand-Cepi receptor pairs, and 12 unique 
Cepi ligand-CS receptor pairs in our observed dataset (Table 2.4).   
 
Table 2.4. The unique compatible ligands and receptors as potential interactions between the Cepi and the 
CS samples when multiple probes from Tables 2.3a and 2.3b are combined (significance of detection calls: 











***CXCL12 ***CXCR4 *CXCL12 ***CXCR4 
*FGF1 **FGFR2 *FGF1 **FGFR2 
*FGF1 *FGFR3 *FGF1 *FGFR3 




**FGF9 *FGFR3 **PDGFA ***PDGFRA 
*HGF *MET **TGFB2 ***TGFBR2 
*PDGFA ***PDGFRA **IL7 *IL7R 
***TGFB2 ***TGFBR2 **IL1B *IL1R1 
*IL7 **IL7R **IL1B *IL1R2 
*WNT2 *FZD2 **WNT2 *FZD2 
**WNT2B *FZD10 **WNT2B ***FZD10 
*WNT7A **FZD7 **WNT7A ***FZD7 
 
 To determine if the observed co-expression of these 17 pairs of compatible 
ligands and receptors (probes) was greater than what would be expected by chance, we 
generated two lists. One list of observed data consisted of the expressed probes of the 17 
CS ligands and 17 compatible Cepi receptors (Table 2.3a), and the other of the 17 
expressed Cepi ligands and 17 CS receptors (Table 2.3b). A second list of random 
associations was generated using the same number of pairings as in the observed list (17 
random pairs) and randomly selecting 17 pairs of ligands and receptors. One randomly 
selected CS (or Cepi) ligand from the pool of the 34 CS (or 36 Cepi) expressed ligands 
(Table 2.2a) was paired with one randomly selected Cepi (or CS) receptor from the pool 
of the 20 Cepi (or 21 CS) expressed receptors (Table 2.2b). These random associations 
were generated 100 times and each time the number of biologically compatible ligand-
receptor pairs arising by chance was counted. The number of biologically compatible 
interactions in the observed data (17) was then compared to the number of compatible 
interactions scored from the randomized associations using Z-statistics. Two types of 
comparisons were performed, one for the pairs of CS ligands and Cepi receptors, and 
another for the pairs of Cepi ligands and CS receptors. For both comparisons, the 
observed number of biologically compatible ligand-receptor pairs was significantly 
greater than what is expected by chance (CS ligands-Cepi receptors z-score= -4.68, p ≤ 
0.0002; Cepi ligands-CS receptors z-score= -4.35, p ≤ 0.0002). Thus, the observed co-
expression of pairs of compatible ligands and receptors is biologically significant.  
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2.3.3 Specific ligand-receptor pairs between Cepi and CS show differential gene 
expression in the two CS classes 
Of the 24 compatible pairs of ligand- and receptor-encoding genes listed in Table 
2.4, most display similar expression patterns between CS1 and CS2. However, 6 of the 
ligand and receptor pairs display differential patterns of expression between the two 
groups of CS suggesting that CS2 may be a more conducive microenvironment for tumor 
growth (Table 2.5). For example, the FGF2 ligand, a documented inhibitor of tumor 
growth [28], is expressed in NS and in CS1 but not in CS2. Since a compatible receptor of 
this inhibitor (FGFR3) is expressed in Cepi, CS2 may be a more conducive 
microenvironment for tumor growth than CS1. The Interleukin 7 (IL7) ligand has been 
previously implicated as an inducer of tumor growth in lymphoblastic leukemia [9], 
prostate cancer [10], breast cancer [11], and colorectal cancer [12]. IL7 is expressed in 
CS2 but not in CS1, again suggesting that CS2 may be a more conducive 
microenvironment for tumor growth than CS1. 
 
Table 2.5. The unique compatible ligands and receptors from Table 2.4 showing the expression pattern in 
NS, CS1, CS2 and Cepi. The 6 highlighted signals had the same expression in NS and CS1 but different 
expression between CS1 and CS2 despite the fact that their compatible signals in Cepi were always 
expressed. Expression is denoted with “+” (i.e., there is at least one Affymetrix present call with detection 
p-value
 




NS LIGANDS CS1 CS2 RECEPTORS Cepi 
+ CXCL12 + + CXCR4 + 
- FGF1 + + FGFR2 - 
- FGF1 + + FGFR3 + 
+ FGF2 + - FGFR3 + 
+ FGF9 + + FGFR3 + 
- HGF + + MET + 




+ TGFB2 + + TGFBR2 + 
- IL7 - + IL7R + 
- WNT2 + + FZD2 + 
+ WNT2B + - FZD2 + 
- WNT7A - + FZD7 + 
NS RECEPTORS CS1 CS2 LIGANDS Cepi 
+ CXCR4 + + CXCL12 + 
+ FGFR2 + + FGF1 + 
- FGFR3 - + FGF1 + 
- FGFR3 - + FGF9 + 
+ PDGFRA + + PDGFA + 
+ TGBFR2 + + TGFB2 + 
+ IL1R1 + + IL1B + 
- IL1R2 + - IL1B + 
+ IL7R + + IL7 + 
+ FZD2 + + WNT2 + 
+ FZD2 + + WNT2B + 
+ FZD7 + + WNT7A + 
 
 The well-documented cancer inducing ligands FGF1 and FGF9 [13-15] are both 
highly expressed in Cepi. The fact that the compatible FGFR3 receptor is expressed in 
CS2 but not in CS1 again suggests that CS2 is a more favorable microenvironment for 
ovarian cancer growth than CS1 
 The WNT family of genes is involved in a variety of developmental processes and 
aberrant expression of various members of WNT genes have been implicated in cancer 
[16].  For example, WNT7A is a ligand present in the extracellular matrix that 
participates in the sexual development of the Mullerian ducts [17]. Recent in vivo mouse 
studies suggest that WNT7A is an inducer of ovarian cancer growth [18]. Consistent with 
this interpretation, WNT7A has recently been identified as a potential early stage 
biomarker of human ovarian cancer [19]. The fact that WNT7A is expressed in CS2 but 
not in CS1 is also consistent with the hypothesis that CS2 may be a more conducive 
microenvironment for ovarian cancer growth than CS1.  
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 A second member of the WNT family, WNT2B, is expressed in CS1 but not CS2 
suggesting, contrary to what is presented above, that CS1 may be more permissive for 
cancer growth. However, the fact that WNT2B has been previously reported to be 
expressed in normal ovaries [20] coupled with our finding that it is also expressed in NS, 
makes interpreting the significance of the dichotomy in WNT2B expression between CS1 
and CS2 ambiguous.  
 
2.4 Discussion 
Cancer progression is a dynamic process involving cellular adaptation and 
survival that is, in part, driven by signaling interactions between participating cells. Many 
signaling interactions have been documented to take place between cancer epithelial cells 
and the surrounding stroma [21]. Early in tumor development, cancer cells produce 
growth factors that are believed to modulate or “activate” the surrounding stroma in order 
to convert the stroma into a supportive microenvironment for cancer growth [2, 13]. For 
example, it has been shown that growth factors secreted by macrophages can contribute 
to cancer progression and metastasis [22]. Other inflammatory cells such as lymphocytes, 
neutrophils, mast cells, T-regulatory cells and platelets also have been shown to have the 
potential to support tumor progression by negatively regulating the anti-cancer host 
immune response [23-25]. Fibroblasts, the major component of the stroma, have been 
shown to be able to participate actively in the malignant progression of cancer by 
producing growth factors, various chemokines and extra cellular matrix components that 
facilitate the production of endothelial cells and pericytes conducive to tumor growth [13, 
26]. 
 The purpose of this study was to investigate the process of stroma activation 
within the context of ovarian cancer. Toward this end, we conducted RNA microarray 
profiling of 45 tissue samples using the Affymetrix (U133 Plus2) gene expression 
platform. Laser capture microdissection (LCM) was used to isolate cancer cells from the 
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tumors of 18 ovarian cancer patients (Cepi). For 7 of these patients, a matched set of 
surrounding cancer stroma (CS) was also collected. For controls, we isolated surface 
epithelial cells (OSE) from the normal (non-cancerous) ovaries of 12 individuals 
including matched sets of samples of OSE and normal stroma (NS) from 8 of these 
patients.  
 Unsupervised hierarchical clustering of the microarray data resulted in the 
expected separation between the OSE and Cepi samples. Consistent with models of 
stromal activation, we also observed significant separation between the NS and CS 
samples. Somewhat unexpected, however, was our finding that the CS samples clustered 
into two distinct sub-groups (CS1 and CS2).  
 Based on patterns of co-expression of ligand and receptor encoding genes, we 
determined that 6 biologically compatible pairs of ligands and receptors are differentially 
expressed between Cepi and the CS1 and CS2 cancer stroma.  The patterns of differential 
expression between the compatible ligands and receptors are consistent with the 
hypothesis that CS2 may be a more conducive microenvironment for tumor growth (Table 
2.5). For example, the expression of tumor promoting ligands in Cepi is always matched 
with the expression of compatible receptors in CS2 but not in CS1.  
 The fact that certain tumor microenvironments are capable of inhibiting tumor 
growth and/or development is well established. For example, macrophages can act as 
anti-cancer agents within the context of the innate immune response [27]. Likewise, 
fibroblasts, in some cellular contexts, have been shown to revert tumor cells to a normal, 
non-cancerous phenotype [28, 29]. Normal ovarian stromal cells have been shown to 
significantly inhibit ovarian cancer cell growth when co-injected into nude mice [30].  
 The apparently innate anti-cancer properties of normal stroma are generally 
considered to be transient giving way to the “activation” of pro-cancer growth signals 
induced by cancer cells as the tumors progress [1]. However, since the majority of the 
patients associated with the CS1 class of cancer stroma have, like the majority of the 
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cancer patients included in our study, already progressed to advanced staged disease 
(Table 2.1), it is unlikely that the CS1 molecular profile represents a transient condition. 
Rather, our results suggest that variability exists among ovarian cancer patients with 
respect to the propensity of normal stroma to become activated.  
 
2.5 Conclusions 
An understanding of the potential clinical significance of the observed molecular 
dichotomy between ovarian cancer stroma is beyond the scope of this present study. 
However, it is relevant to note that all of the cancers associated with the putatively more 
permissive CS2 cancer stroma were classified as grade 3 while those associated with the 
putatively more resistant CS1 cancer stroma were classified as grade 2. The fact that no 
distinction was apparent between the molecular profiles of grade 2 and grade 3 Cepi 
samples (Figure 2.1), suggests that cancer grade may, at least in part, be determined by 
the relative permissiveness of the tumor microenvironment. Molecular profiling of larger 
numbers of matched sets of ovarian cancer and stroma samples will be required to 
adequately test this hypothesis. Nevertheless, the current results are consistent with the 
hypothesis that the microenvironment plays a significant role in ovarian cancer 
development and suggest that functionally significant variability may exist among 
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MOLECULAR PROFILING SUPPORTS THE ROLE OF 
EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) IN 
OVARIAN CANCER METASTASIS 
 
3.1 Introduction 
While metastasis ranks among the most lethal of all cancer-associated processes, 
on the molecular level, it remains one of the least well understood [1]. One model that 
has gained credibility in recent years is that metastasizing cells at least partially 
recapitulate the developmental process of epithelial-to-mesenchymal transition (EMT) in 
their transit from primary to metastatic sites [2, 3].  While experimentally supported by 
cell culture and animal model studies (e.g., [4-7]), the lack of unambiguous confirmatory 
evidence in cancer patients has led to persistent challenges to the model’s relevance in 
humans [8, 9]. We report here the results of gene expression profiling of 14 matched sets 
of primary and metastatic ovarian cancer (serous adenocarcinoma) patient samples. 
While histological examination reveled no morphological distinction between 
matched sets of primary and metastatic samples, gene expression profiling clearly 
distinguished two classes of metastatic samples. One class displayed expression patterns 
statistically indistinguishable from primary samples isolated from the same patients while 
a second class displayed expression patterns significantly different from primary samples. 
Further analyses focusing on genes previously associated with EMT clearly distinguished 
the primary from metastatic samples in all but one patient. Our results are consistent with 
a role of EMT in most if not all ovarian cancer metastases and demonstrate that identical 
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morphologies between primary and metastatic cancer samples is insufficient evidence to 
negate a role of EMT in the metastatic process.  
 
3.2 Materials and Methods 
3.2.1 Tissue collection 
Tissues were collected at Northside Hospital (Atlanta, GA) under appropriate 
Institutional Review Board protocols. Following resection, the tumor tissues were placed 
in cryotubes and immediately (<1 minute) frozen in liquid nitrogen. Samples were 
transported on dry ice to Georgia Institute of Technology (Atlanta, GA), and stored at -80 
ºC. After examination and verification by a pathologist, tissues were embedded in 
cryomatrix (Shandon). The clinical information of the primary and metastatic cancer 




Age Histopathology Stage Grade Morphological Comparison  





IV 3 Right ovary vs. Omentum: Similar 
morphology 
528 66 Serous 
Adenocarcinoma 
IIIc 3 Right ovary vs. Omentum: Similar 
morphology 
542 61 Serous 
Adenocarcinoma 
IV 3 Left ovary vs Omentum:  Similar 
morphology 
551 59 Serous 
Adenocarcinoma 
IIIc/IV 3 Right ovary vs. omentum: Similar 
morphology 
588 71 Serous 
Adenocarcinoma 
IIIc 2/3 Right ovary vs. Omentum:  Similar 
morphology  
617 64 Serous 
Adenocarcinoma 
IIIc 2/3 Left ovary vs. omentum:  Similar 
morphology 
620 62 Serous 
Adenocarcinoma 
III/IV 3 Left ovary vs. omentum:  Similar 
morphology 
 
Figure 3.1 (a) Tissues from the primary and metastatic samples of the patients in the study display 
indistinguishable morphologies. (b) Clinical information of the patients in the study. 
 
For each of the primary and metastatic (omental) tissue samples, 7μm frozen 
sections were cut and attached to uncharged microscope slides. Immediately following 
dehydration and staining (HistoGene, LCM Frozen Section Staining Kit, Arcturus. Life 
Technologies), slides were processed in an Autopix (Arcturus) instrument for laser 
capture microdissection (LCM). CapSure Macro-LCM Caps (Arcturus, Life 
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Technologies) were used to ensure purity of all primary cancer epithelial cells and 
omental metastatic cells. Approximately 30,000 cells were collected for each of the 14 
tissue samples (seven primary and seven matched metastatic ovarian cancer samples). 
 
3.2.2 RNA extraction and amplification 
PicoPure RNA Isolation Kit (Life Technologies) protocols were followed for 
RNA extraction from the cells on the Macro-LCM caps in 30µL of extraction buffer. 
RNA quality was verified for all samples on the Bioanalyzer RNA Pico Chip (Agilent 
Technologies). Total RNA from the above extractions was processed using the Ovation® 
Pico WTA System (NuGEN) in conjunction with the Encore™ BiotinIL Module 
(NuGEN), to produce an amplified, biotin-labeled cDNA suitable for hybridizing to 
GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix) following manufacturer's 
recommendations. 
 
3.2.3 Microarray data analysis 
Gene analysis: Fourteen individual gene expression profiles were generated from 
the primary and matched metastatic samples of each of the seven patients used in this 
study. The 14 Affymetrix .CEL files were processed using the Affymetrix Expression 
Console (EC) Software Version 1.1 using the Robust Multi-Array Average (RMA) 
normalization method. The normalized expression values from all 14 samples were log2 
transformed. From the initial log2 transformed 54,675 probe sets (21,049 probe sets 
transformed, unique, annotated genes), 50,286 that displayed marginal differences in 
expression across all patient samples (standard deviation ≤ 0.8 from the mean of all 14 
samples) were filtered out. The remaining 4,389 probe sets (3,365 genes) were employed 
in the unsupervised clustering analysis (Figure 3.2). 
For the identification of the epithelial to mesenchymal transition (EMT) related 
genes, a list of 84 genes, previously implicated in the process of EMT, was employed 
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(Table A.3.2 (http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-090Z.html). 
Of these genes, 39 (61 probe sets) were identified among the 3,365 genes (4,389 probe 
sets) differentially expressed across samples (Figure 3.2, Table A.3.1). 
Individual clustering analyses were carried out for matched sets of primary and  
metastatic samples from the Group 1 (Figure 3.2b) and Group 2 (Figure 3.2c) patients.  
Gene clustering metrics: All hierarchical clustering (Figure 3.2, Figure 3.3) was 
performed using normalized Z-scores of the log2 transformed expression values. 
Functional pathway enrichment: Biological interpretations of the differential gene 
expression data were performed by pathway enrichment analysis using MetaCore 5.2 




EMT is a process by which epithelial cells acquire mesenchymal cell 
characteristics including reduced cell adhesiveness and increased cell motility [10]. The 
process is an essential component of embryonic development and is known to be both 
transient and reversible (mesenchymal-to-epithelial transition or MET). Initial 
observations that many characteristics of cancer metastasis appear to be recapitulations of 
key features of EMT/MET, led to the hypothesis that similar, if not identical, molecular 
mechanisms may be involved [11]. While numerous subsequent studies conducted in cell 
lines and animal models have supported this hypothesis (e.g., [4-7]), the lack of 
unambiguous evidence from studies involving human tumor samples has resulted in 
skepticism [8, 9]. One persistent objection to the model is the fact that careful 
morphological examinations of human metastases have never uncovered the existence of 
cancer mesenchymal-like cells [8]. Indeed, while it is clear that cancer metastasis must 
involve detachment of cancer cells from the primary tumor, such a phenomenon could 
well be attributed to mutation(s) and/or aberrant gene expression patterns in one or a few 
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genes and not necessarily reflect involvement of a more coordinated process such as 
EMT [8]. Although these alternative possibilities are not mutually exclusive, a 
clarification of the molecular mechanism(s) underlying metastasis is critical because it 
could have significant ramifications on future directions in the development of diagnostic 
tests and potential anti-metastatic drugs [12].  
Ovarian cancer is the most malignant of all gynecological cancers and is 
responsible for over 14,000 deaths per year in the United States alone [13].  Because 
ovarian cancer is often asymptomatic early in its progression (Stages I/II), the disease is 
not typically diagnosed until later stages (Stages III/IV) when the cancer has metastasized 
and prognosis is poor (5 year survival < 30%) [13]. Ovarian cancer metastasis is 
primarily due to the exfoliation of malignant cells or cell aggregates from the primary 
tumor into the abdominal cavity and their subsequent spread and attachment to visceral 
and parietal peritoneal surfaces of abdominal organs such as the omentum. This 
mechanism of intra-abdominal metastatic spread allows for the capture and molecular 
comparison of primary and metastatic cancer cells isolated from the same patient, 
providing a favorable opportunity to evaluate the potential role of epithelial-to-
mesenchymal transition (EMT) in the metastatic process.  
Fourteen matched sets of primary and metastatic (omental) samples were 
collected from seven advanced staged (III/IV) ovarian cancer (serous adenocarcinoma) 
patients. Pathological examination classified all of the cancer samples as highly un-
differentiated with no significant difference in morphology between any of the primary 
and metastatic sets (Figure 3.2).  Tissue samples for molecular analysis were snap frozen 
in liquid nitrogen within one minute of surgical removal and subsequently embedded in 
cryomatrix (Shandon) for frozen sectioning and laser capture microdissection (LCM). 
Approximately 30,000 cancer epithelial cells were isolated from each tissue sample and 
RNA was extracted and processed for gene expression analysis (Affymetrix, U133Plus 




Figure 3.2. Unsupervised classification of differentially expressed genes between primary and 
metastatic samples identifies two groups of patients. (a) Unsupervised hierarchical clustering performed 
on 3,365 unique, annotated genes (4,389 probe sets) displaying significant expression variation across all 
samples (SD ≥ 0.8). Primary and metastatic samples from 5 patients (617, 542, 551, 620, 588) clustered 
closely to one another (Group1) while primary and metastatic samples from 2 patients (489, 528) clustered 
distantly from one another (Group 2); (b) Unsupervised hierarchical clustering of the same genes/probe sets 
in (a) across primary (P) and metastatic (M) samples of Group 1 patients. All P samples cluster most 
closely with their matched M samples for all patients; (c) Unsupervised hierarchical clustering of the same 
genes/probe sets in (a) across primary (P) and metastatic (M) samples of Group 2 patients. The P samples 
do not cluster with the matched M samples of the same patient. 
 
Analysis of expression profiles for the 14 primary and metastatic samples 
identified 3,365 genes (4,389 probe sets) as being significantly differentially expressed 
(Table A.3.1). Unsupervised hierarchical clustering of these data revealed that the 
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metastatic samples of five of the seven patients grouped closely with their respective 
primary samples (Figure 3.2a, b, Group 1). In contrast, the metastatic samples from two 
of the patients (489M and 528M) clustered most closely with one another and distant 
from their respective primary samples (Figure 3.2a, c, Group 2).  Functional pathway 
analysis was carried out incorporating the 3,365 differentially expressed genes described 
above. The results indicated that 13 of the 20 most significantly enriched pathways are 
associated with EMT or EMT-related functions (i.e., cytoskeleton remodeling, cell 
adhesion, etc., Table 3.1). 
 
Table 3.1. The 20 most significantly enriched pathways between all primary and metastatic samples. 
Enriched pathways were computed utilizing the 3,365 significantly differentiated expressed genes (4,389 
probe sets) represented in the clustering analysis (Figure 3.2). Thirteen of the 20 pathways (highlighted in 
bold) are involved in EMT or EMT-related processes (i.e., cytoskeleton remodeling, cell adhesion, EMT 
developmental processes, MIF-associated cell adhesion).  
 
  Functional Pathways pValue 
1 Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 1.53E-13 
2 Cell adhesion_ECM remodeling 1.03E-11 
3 Cytoskeleton remodeling_Cytoskeleton remodeling 7.54E-11 
4 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 9.43E-11 
5 Cell adhesion_Chemokines and adhesion 1.75E-10 
6 Oxidative phosphorylation 1.99E-10 
7 Development_TGF-beta-dependent induction of EMT via MAPK 2.05E-09 
8 DNA damage_Brca1 as a transcription regulator 3.36E-09 
9 Cytoskeleton remodeling_Reverse signaling by ephrin B 6.64E-09 
10 LRRK2 in neurons in Parkinson's disease 2.32E-08 
11 Apoptosis and survival_BAD phosphorylation 5.22E-08 
12 Development_TGF-beta-dependent induction of EMT via RhoA,  PI3K and ILK 5.30E-08 
13 Cytoskeleton remodeling_Role of PKA in cytoskeleton reorganisation 1.30E-07 
14 Transcription_Androgen Receptor nuclear signaling 2.02E-07 
15 Immune response_MIF-induced cell adhesion, migration and angiogenesis 3.06E-07 
16 Immune response_MIF - the neuroendocrine-macrophage connector 3.06E-07 
17 Development_TGF-beta-dependent induction of EMT via SMADs 5.02E-07 
18 Cell adhesion_Integrin-mediated cell adhesion and migration 6.77E-07 
19 Transport_Clathrin-coated vesicle cycle 7.47E-07 
20 Cell adhesion_Role of tetraspanins in the integrin-mediated cell adhesion 1.27E-06 
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To explore the possibility that differences in the expression of EMT-associated 
genes may contribute to the dichotomy between Group 2 primary and metastatic samples, 
we conducted additional analyses focusing on genes previously established to be directly 
or indirectly involved in the EMT process (Table A.3.2). Thirty-nine of these EMT-
associated genes (61 probe sets) are among the 3,365 genes (4,389 probe sets) used in our 
clustering analysis (Figure 3.2).  Figure 3.3 presents a comparative ranking of these 39 
EMT-associated genes with respect to fold-change differences in expression between the 
Group 1 and Group 2 primary and metastatic samples.   
 
 
Figure 3.3. Comparative ranking of EMT-associated genes with respect to fold-change differences in 
expression between the Group 1 and Group 2 primary and metastatic samples. Thirty-nine previously 
characterized EMT associated genes were identified among the 3,365 genes significantly differentially 
expressed across 14 tissue samples (see Figure 1). Histograms depict the fold change differences in 
expression between primary and metastatic samples of Group 1 and Group 2 patients. Although EMT-
associated genes are more differentially expressed between primary and metastatic samples from Group 2 
than Group 1 patients, Group 1 patients also display large fold differences for some EMT-associated genes. 
These findings suggest that the observed differences in expression of EMT-associated genes between the 
primary and metastatic samples of Group 1 vs. Group 2 patients represent differences in a continuum of the 
EMT-MET process rather than its occurrence in one and absence in the other.  
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Nearly 74% (45/61) of the EMT-associated probe sets display a > 2-fold change 
in expression in the Group 2 metastatic samples while only 18% (11/61) display a > 2-
fold difference in expression in the Group 1 metastatic samples. In addition, a number of 
the differences in expression are consistent with the hypothesis that, on the molecular 
level, Group 2 metastatic samples are more mesenchymal-like than their matched primary 
samples. For example, the expression of several “mesenchymal biomarkers”, i.e., VIM 
(vimentin), TMEFF1 (transmembrane protein with EGF-like and two follistatin-like 
domains 1), ITGAV (integrin alpha-V), and ZEB1 (zinc finger E-box-binding  
homeobox1) are all up-regulated (2 to 3-fold) in Group 2 metastatic samples while being 
essentially unchanged between Group 1 primary and metastatic samples. However, a 
number of other genes typically up-regulated during EMT [e.g., COL3A1 (collagen type 
III alpha-1), FN1 (fibronectin), VCAN (vesican), and MMP2 (matrix metalloproteinase-
2] were not only up-regulated in Group 2 metastatic samples but in Group 1 metastatic 
samples as well, albeit at generally lower levels. These findings suggest that the observed 
differences in expression of EMT-associated genes between the primary and metastatic 
samples of Group 1 vs. Group 2 patients represent differences in a continuum of the 
EMT-MET process rather than its occurrence in one and absence in the other.  
To explore this possibility further, we conducted a second clustering analysis 
using only genes previously implicated in EMT (Table A.3.2). The results presented in 
Figure 3.4 demonstrate that with respect to these EMT-associated genes, the primary 
sample of only one patient (620) remained most closely clustered with its metastatic 
counterpart. The primary and metastatic samples of all of the remaining patients 




Figure 3.4. Unsupervised classification of 39 differentially expressed EMT associated genes (61 probe 
sets) demonstrates significant divergence between most primary and metastatic samples. 
Unsupervised hierarchical clustering of EMT associated genes differentially expressed across all samples 
demonstrates that the primary and metastatic samples of only one patient (620) are clustered most closely 
with one another. Primary and metastatic samples of all other patients cluster away from one another 
consistent with a model whereby all of the metastatic samples have undergone EMT while displaying a 
range of partial or complete (patient 620) compensating MET transitions at the metastatic site. The 
alternative hypothesis that metastasis occurs in the absence of EMT is definitively consistent with the 
molecular profiles of only one Group 1 patient (620).  
 
Collectively, our results are consistent with a model whereby all of the metastatic 
samples have undergone EMT while displaying a range of partial or complete (patient 
620) compensating MET transitions at the metastatic site. The alternative hypothesis that 
metastasis occurs in the absence of EMT is definitively consistent with the molecular 
profiles of only one Group 1 patient (620). 
The majority of cancer-related deaths are attributable to metastases rather than to 
primary tumors [1]. For this reason, there is considerable interest in understanding the 
molecular mechanisms underlying the process with the hope that such knowledge may 
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lead to more effective therapeutic treatments [12]. Considerable evidence has 
accumulated in recent years from innumerable in vitro
 
and animal model studies e.g., [4-
7],  indicating that EMT is playing a key role in the metastatic spread of cancer cells from 
primary sites. Despite the significant body of support for this model, the lack of definitive 
clinical evidence in human cancer patients has resulted in persistent and spirited 
skepticism  [8, 9].  Much of this skepticism is based upon the fact that human metastatic 
samples consistently display morphologies indistinguishable from the primary tumors 
from which they are derived. 
In an effort to help resolve this controversy, we conducted morphological and 
molecular analyses of 14 matched sets of primary and metastatic samples from late 
staged (III/IV) ovarian cancer patients. Pathological examination revealed no 
morphological differences between any of the primary and metastatic samples.  In 
contrast, gene expression analyses identified two distinct groups of patient samples. In 
one group, the molecular profiles of primary and metastatic samples from the same 
patient displayed indistinguishable molecular profiles. While this result is not 
inconsistent with an EMT model where mesenchymal-like metastasizing cells have 
undergone a compensating MET transition at the metastatic site, the results are equally 
consistent with the hypothesis that metastasis in these patients did not involve EMT. 
However, molecular profiling also identified a second group of patient samples where the 
metastatic samples from different patients clustered together and were clearly distinct 
from their respective primary samples. Further analyses demonstrated that differences in 
the expression patterns of genes previously associated with EMT clearly separated the 
primary and metastatic samples isolated from all but one patient. Collectively, our results 
support a role of EMT in ovarian cancer metastases and demonstrate that 
indistinguishable morphologies between primary and metastatic cancer samples is not 
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